HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 275, Issue 28, 21262-21271, July 14, 2000

This Article Abstract Full Text (PDF) All Versions of this Article: 275/28/21262    most recent M002310200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liadaki, K. N. Articles by Zannis, V. I. Search for Related Content PubMed PubMed Citation Articles by Liadaki, K. N. Articles by Zannis, V. I. Social Bookmarking                      What's this?

Binding of High Density Lipoprotein (HDL) and Discoidal Reconstituted HDL to the HDL Receptor Scavenger Receptor Class B Type I^*

EFFECT OF LIPID ASSOCIATION AND APOA-I MUTATIONS ON RECEPTOR BINDING^*

Kalliopi N. Liadaki^§, Tong Liu^§¶, Shangzhe Xu^§, Brian Y. Ishida^§**, Philippe N. Duchateaux^**, Jonathan P. Krieger, John Kane, Monty Krieger, and Vassilis I. Zannis^¶§§

From the  University of Crete, Department of Biochemistry and Institute of Molecular Biology and Biotechnology, Heraklion, Crete, Greece 71110, the  Biology Department, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, the  Cardiovascular Research Institute, School of Medicine, University of California, San Francisco, California 94143, the ^** Department of Medicine, University of California, San Francisco, California 94143, and the ^¶ Section of Molecular Genetics, Whitaker Cardiovascular Institute, Department of Medicine and Biochemistry, Boston University Medical Center, W-509, Boston, Massachusetts 02118

Received for publication, March 15, 2000, and in revised form, April 26, 2000

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

The binding of apoA-I-containing ligands to the HDL receptor scavenger receptor class B type I (SR-BI) was characterized using two different assays. The first employed conventional binding or competition assays with ¹²⁵I-labeled ligands. The second is a new nonradioactive ligand binding assay, in which the receptor-associated ligand is detected by quantitative immunoblotting ("immunoreceptor assay"). Using both methods, we observed that the K_d value for spherical HDL (density = 1.1-1.13 g/ml) was ~16 µg of protein/ml, while the values for discoidal reconstituted HDL (rHDL) containing proapoA-I or plasma apoA-I were substantially lower (~0.4-5 µg of protein/ml). We also observed reduced affinity and/or competition for spherical ¹²⁵I-HDL cell association by higher relative to lower density HDL and very poor competition by lipid-free apoA-I and pre--1 HDL. Deletion of either 58 carboxyl-terminal or 59 amino-terminal residues from apoA-I, relative to full-length control apoA-I, resulted in little or no change in the affinity of corresponding rHDL particles. However, rHDL particles containing a double mutant lacking both terminal domains competed poorly with spherical ¹²⁵I-HDL for binding to SR-BI. These findings suggest an important role for apoA-I and its conformation/organization within particles in mediating HDL binding to SR-BI and indicate that the NH₂ and COOH termini of apoA-I directly or indirectly contribute independently to binding to SR-BI.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

SR-BI¹ is a high affinity HDL receptor that recognizes apoA-I and other apolipoproteins (1, 2). Following HDL binding to SR-BI, cells selectively take up cholesteryl esters, and their intracellular concentration increases as a function of time (2). SR-BI is predominantly expressed in steroidogenic tissues and the liver (2, 3). Overexpression of SR-BI in mice following infection with recombinant adenoviruses or in transgenic mice dramatically decreases plasma HDL cholesterol levels, increases biliary cholesterol levels, and suppresses atherosclerosis (4-8, 82). Disruption of the SR-BI gene in mice increases by more than 2-fold plasma HDL cholesterol levels without altering plasma apoA-I levels; increases the size of HDL; decreases the cholesterol content of the adrenal gland, ovary, and bile (9, 10); and induces dramatically accelerated atherosclerosis in apoE knockout mice (10). These data suggest that SR-BI plays an important role in the last steps of murine reverse cholesterol transport and in the delivery of HDL cholesterol to steroidogenic tissue for maintenance of cholesteryl ester stores and the synthesis of steroid hormones. In addition, female homozygous null SR-BI knockout mice are infertile (10).

In addition to mediating binding to SR-BI, apoA-I in HDL can directly or indirectly promote the efflux of cholesterol from peripheral cells (11), and regulate lecithin:cholesterol acyltransferase activity (12, 13). Thus, apoA-I may play an important role in regulating the cholesterol content of peripheral tissues either through selective cholesterol delivery or cholesterol efflux pathways (11, 14-16).

In the current study, we have focused on the SR-BI binding of different apoA-I-containing ligands, including spherical HDL isolated by ultracentrifugation or immunoaffinity chromatography, pre--1 HDL, lipid-free apoA-I, and reconstituted HDL (rHDL) particles containing wild-type and truncated apoA-I forms. We have used standard "radioreceptor" binding assays (2), in which the ligands are labeled with ¹²⁵I on their protein moieties. To ensure that ¹²⁵I labeling of the ligands did not affect their binding to SR-BI, we developed a new "immunoreceptor assay," which permits analysis of binding without the need to radiolabel the ligands. The binding parameters determined using the immunoreceptor assay were similar to those determined using the standard radioreceptor assay. Using both assays for direct binding measurements as well as competition experiments, we have shown that apoA-I's affinity for SR-BI was higher when it was incorporated into discoidal rHDL particles than when it was present in spherical HDL (HDL₂ or HDL₃),  HDL, pre--1 HDL, or when it was lipid-free. Higher density spherical HDLs bound less tightly to SR-BI than did lower density HDLs. Analysis of rHDL particles containing truncated apoA-I forms showed that deletion of either the carboxyl-terminal sequence 185-243 (apoA-I:(185-243)) or the amino-terminal sequence 1-59 (apoA-I:(1-59)) resulted in little or no change in the affinity of the corresponding rHDL particles for SR-BI. In contrast, rHDL particles containing a double mutant lacking both of these amino and carboxyl-terminal regions competed poorly for the binding of native HDL to SR-BI.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Materials

The Klenow fragment of DNA polymerase I, T4 ligase, polynucleotide kinase, and restriction enzymes were purchased from New England Biolabs. Calf intestinal alkaline phosphatase was purchased from Stratagene (La Jolla, CA), and Vent polymerase was from Promega. Other materials for the polymerase chain reaction were obtained from Perkin-Elmer. The Sequenase sequencing kit was purchased from U. S. Biochemical Corp. Materials for oligonucleotide synthesis were purchased from Applied Biosystems. Bactotryptone and bacto-yeast extract were obtained from VWR (Pittsburgh, PA). Dulbecco's modified Eagle's medium and Sf-900 II SFM medium were provided by Life Technologies, Inc. Other reagents (and sources) were as follows: sodium [¹²⁵I]iodide (Amersham Pharmacia Biotech); fatty acid-free bovine serum albumin, cholesterol, sodium cholate, 1-palmitoyl-2-oleoyl-L-phosphatidylcholine (POPC), aprotinin, benzamidine, leupeptin, and phenylmethylsulfonyl fluoride (Sigma); dialysis tubing (Spectrum Medical Industries, Inc., Los Angeles, CA); Ham's F-12 medium, fetal bovine serum, and trypsin/EDTA (JRH Biosciences, Lenexa, KS); penicillin/streptomycin, glutamine, and G418 sulfate (Life Technologies), immunoblot polyvinylidene difluoride membrane (Bio-Rad); monoclonal anti-human apoA-I antibody 5F-6 (Ottawa Heart Institute, Ontario, Canada); anti-mouse IgG conjugated to horseradish peroxidase and 3',3'-diaminobenzidine or enhanced chemiluminescence (ECL) reagent (Amersham Pharmacia Biotech). All other reagents were purchased from Sigma, Bio-Rad, or other standard commercial sources as described previously (1).

Methods

Plasmid Constructions and Generation of Cell Lines Expressing ProapoA-I and ApoA-I:(185-243)-- The fourth exon of the human apoA-I gene was amplified and mutagenized by polymerase chain reaction, using a set of specific mutagenic primers (185S, 185A), containing the mutation of interest (a stop codon at nucleotide 185), and a set of flanking universal primers (AINotI, AIXhoI), containing the restriction sites NotI and XhoI. The sequences of the primers used are shown in Table I. The pUCA-I_N* vector, which contains a NotI site in intron 3 and an XhoI site in the 3'-end of the apoA-I gene, was used as a template in the amplification reactions (18). The DNA fragment containing the mutation of interest was digested with NotI and SalI and cloned into the NotI and XhoI sites of the pBMT3X-AI vector. The variant apoA-I sequences were verified by DNA sequencing.

Permanent cell lines in mouse mammary tumor C127 cells expressing the wild-type proapoA-I and the carboxyl-terminal truncation apoA-I:(185-243) were generated as described previously (18). C127 cell clones overproducing the wild-type and the variant apoA-I form were grown in roller bottles on collagen-coated lead microspheres (Verax Corp.), and the protein was purified from the serum-free medium as described previously (18).

Generation of Amino- and Carboxyl-terminal ApoA-I Deletion Constructs: Expression in the Baculovirus System and Protein Purification-- To generate the recombinant baculoviruses expressing wild-type and mutant apoA-I forms, a BamHI-SalI fragment containing human apoA-I cDNA was cloned into the polylinker region of pFASTBAC donor plasmid, which contains the ampicillin and gentamycin resistance genes (Life Technologies). This recombinant plasmid also contains a histidine tag and the tobacco etched viral protease cleavage site. The apoA-I-containing plasmid was used to transform DH10 Bac Escherichia coli cells (Life Technologies). These cells had been transformed previously with the baculovirus genome containing the lacZ and kanamycin resistance genes, along with a helper plasmid containing the tetracycline resistance gene and the transposase genes. Transposition of the apoA-I gene into the lacZ gene disrupts the expression of lacZ and provides a recombinant plasmid named bacmid. For the generation of the donor plasmid expressing the apoA-I:(1-59) form, the apoA-I region between amino acid 60 and the end of 3'-untranslated region was amplified using 5' (AIM2-5) and 3' (AIM1-3) primers (see Table I). The 5' and 3' primers contain BamHI and SalI restriction sites, respectively. The amplified fragment was digested with BamHI and SalI and cloned into the corresponding sites of the pFASTBAC donor plasmid. For the generation of the donor plasmid expressing the (1-59 and 185-243) A-I, the region between amino acids 60 and 184 was amplified using the 5' (AIM2-5) and 3' (AIM3-3) primers, respectively (see Table I). The AIM3-3 primer introduces a stop codon at position 185 and contains a SalI restriction site. The amplified fragment was digested with BamHI and SalI and cloned into the corresponding sites of the pFASTBAC donor plasmid. For the generation of the wild-type apoA-I donor plasmid (pFASTBAC-A-I), the 3' apoA-I Bsu36I-SalI region between codon 81 and the SalI polylinker site of the plasmid was obtained by restriction digestion. The region corresponding to amino acids +1 to 82 was amplified using the 5' (AIC-5) and 3' (AIC-3) primers of Table I. The 5' and 3' primers contain restriction sites for BamHI and Bsu36I, respectively. The amplified fragment was digested with BamHI and Bsu36I and ligated along with the 3' Bsu36I-SalI fragment of apoA-I into the BamHI and SalI sites of the pFASTBAC^TM HTb plasmid to generate the pFASTBAC-A-I donor plasmid. Cells containing recombinant bacmids were selected by kanamycin, tetracycline, and gentamycin resistance, as white colonies, due to the disruption of lacZ sequence in the recombinant bacmid. Recombinant bacmid DNA was isolated from minipreps and used to infect a monolayer of Sf-9 insect cells (19-21). Recombinant viruses were isolated, amplified, titrated, and used to infect larger Sf-9 cell cultures grown in suspension at 27 °C. Sf-9 cells were pelleted and resuspended in a lysis buffer. The supernatant was used for the purification of apoA-I fusion proteins using a Ni²⁺-nitrilotriacetic acid resin affinity column (22, 23). The pure apoA-I without the His tag, when needed, was obtained by cleavage with recombinant tobacco etched viral protease and purified by a second Ni²⁺-nitrilotriacetic acid resin affinity column.

Lipoprotein Isolation, Labeling, and Characterization-- Blood was obtained from healthy fasting human donors. Spherical HDL (density range 1.09-1.18 g/ml) was prepared from pooled plasma (two donors for each preparation) by zonal centrifugation as described previously (24) and was stored under nitrogen at 4 °C. ¹²⁵I-Labeled HDL (296-649 cpm/ng protein) and ¹²⁵I-labeled apoA-I (358-470 cpm/ng protein) were prepared using the iodine monochloride method (25). Unless otherwise noted, the HDL fractions that were used for iodination and subsequently in the competition experiments were in the density range 1.1-1.14 g/ml. The protein concentrations of the HDL preparations, apolipoproteins, and cell lysates were determined by the method of Lowry et al. (26). The apolipoprotein composition of the preparations was assessed by Coomassie Brilliant Blue staining of gradient (6-20%) SDS-polyacrylamide gels. Native and radiolabeled HDL preparations were periodically monitored, and preparations were discarded if evidence of abnormal electrophoretic mobility, presumably due to radiolysis/oxidation, was observed. The binding properties of such modified HDLs differ from those of native HDL (e.g. increased binding affinity for SR-BI; not shown).

Pre--1 HDL Purification from Plasma-- Pre--1 HDL and  HDL were purified from freshly drawn venous blood under nondenaturing conditions as described by Kunitake et al. (27) with the following modifications. Typically, blood pooled from two donors (360 ml) is drawn into a mixture containing 1 mM sodium EDTA, 0.02% NaN₃, 10 µg/ml -2 macroglobulin, 0.13% -aminocaproic acid, 0.3 mg/ml benzamidine, 1 µg/ml gentamycin sulfate and cooled immediately on ice, and plasma is separated by low speed centrifugation (1,800 × g, 30 min). Plasma aliquots (20 ml) were subjected to anti-apoA-I (affinity-purified IgG) immunoaffinity column chromatography. The binding fraction consisting of apoA-I-containing lipoproteins (LpA-I) was eluted with 0.2 M acetic acid (pH 3.0) and immediately neutralized to pH 7.0 with 2 M Tris buffer. The fraction was further processed over Sepharose columns covalently coupled with affinity-purified anti-human serum albumin IgG and protein A. The pooled LpA-I material was reduced in volume by ultrafiltration (spiral ultrafiltration cartridge, type S3Y10 (Amicon), Ultrafree (5,000 molecular weight cut-off; Millipore Corp.) and resolved by preparative slab gel-agarose electrophoresis into five discrete fractions (, pre--1, pre--2, -1, ). Pre--1 HDL from the pre--1 and pre--2 zones was recovered by electroelution and subjected to molecular sieve and anion exchange chromatography. Molecular sieve chromatography consisted of two Superose 12 columns (Amersham Pharmacia Biotech) connected in series operating at 0.03 ml/min at 3 °C in 10 mM Tris (pH 7.4), 0.15 M NaCl, 1 mM EDTA, 0.02% NaN₃. Anion exchange chromatography consisted of two (1-ml) Hi Trap Q columns (Amersham Pharmacia Biotech), connected in series and operated at 0.5 ml/min at 3 °C. Pre- HDL eluted in 10 mM Tris (pH 8.5), 40 mM NaCl. Pre--1 HDL was characterized for particle size distribution by electrophoresis through a 2-45% concave acrylamide gradient gel in a vertical gel apparatus (MiniProtean; Bio-Rad) modified for cooling at 10 °C for 3,000 V-h. Calibrator proteins (high molecular weight; Pharmacia) were supplemented with human low density lipoprotein (d = 1.030-1.050 g/ml) and molecular sieve-purified ovalbumin to yield a dynamic Stokes radii range of 3.0-12.5 nm. Analysis by SDS-polyacrylamide gel electrophoresis (2-25% linear acrylamide gradient) revealed the presence of a single apoA-I band free of proteolytic peptides. Preparations exhibiting evidence of apoA-I proteolysis were discarded. Typically, 2 mg of pre--1 HDL were obtained with an overall recovery of 15%. Yields depend in part on the starting plasma levels, which vary among individual donors, as determined by quantitative agarose immunoblotting (28) and isotope dilution ultrafiltration assays (29).

Preparation of rHDLs of Apolipoprotein, POPC, and Cholesterol-- Purified apolipoprotein A-I was prepared from plasma as described previously (30). Complexes comprising apolipoprotein, POPC, and cholesterol were prepared using the sodium cholate dialysis method (31) using an apoA-I/POPC/cholesterol molar ratio of 1:100:10, as previously reported (1). Apolipoprotein-lipid complex formation was verified by analysis with native polyacrylamide gradient (8-25%) gel electrophoresis (Pharmacia Phast gel system; Amersham Pharmacia Biotech). The lipid-free apoA-I that was not incorporated in the lipid protein complexes was removed from the preparation either by dialysis using a dialysis membrane with a molecular weight cut-off of 50,000 or by gel filtration using an Amersham Pharmacia Biotech Superose 6HR column, 10/30 (total bed volume 24 ml).

Cell Cultures for Receptor Binding Assays-- Control (ldlA-7) cells and a cell line expressing murine SR-BI receptor derived from ldlA-7 cells (ldlA[mSR-BI]) have been described previously (2, 32-34). The ldlA-7 cells were maintained in monolayer culture in Ham's F-12 medium containing 5% fetal bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin, and 2 mM glutamine (medium A). The ldlA[mSR-BI] cells were maintained as stock cultures in medium A supplemented with 500 µg/ml G418 (medium B). All incubations with cells were performed at 37 °C in a humidified 5% CO₂, 95% air incubator.

Cell Association and Competition Assays Using ¹²⁵I-Labeled Ligand (Radioreceptor Assay)-- SR-BI activity at 37 °C was assessed by measuring cell association of radiolabeled ligands, as described previously (1, 2, 33, 35, 36). For direct association saturation curves, incubations were performed in the absence (total cell association, duplicate determinations) or presence (nonspecific cell association, single determinations) of a 40-fold protein mass excess of unlabeled HDL. For competition curves, duplicate incubations were performed in the absence or presence of the indicated unlabeled competitors. The cell association of ¹²⁵I-ligands was analyzed as a function of concentration by nonlinear regression (using the Prism program). The best fit was found for the model with high affinity binding to a specific site plus low affinity binding to other sites (background) as described below for the immunoreceptor assay. The specific, high affinity cell association activities presented in the saturation curves represent the differences between the average total cell association and nonspecific cell association values and are expressed as ng of protein of HDL or apolipoprotein complex associated per mg of total cell protein. The total cell association values presented in the saturation curves are expressed as ng of protein of HDL or apolipoprotein complex associated with the cells per mg of total cell protein. Cell association for the competition assays is presented as the average percentage of control values determined in the absence of inhibitors. Each of the binding/competition experiments shown is representative of the results obtained in at least two and often four or more independent experiments.

Immunoreceptor Assay-- To measure the cell association of unlabeled ligands, we used the following assay. On day 0, ldlA-7 and ldlA[mSR-BI] cells were plated in six-well dishes at 3 × 10⁵ cells/well in medium A (ldlA-7) or medium B (ldlA[mSR-BI]). On day 2, the monolayers were washed twice with Ham's F-12 medium and then refed with 0.7-1 ml of medium C (Ham's F-12 medium containing 0.5% (w/v) fatty acid-free bovine serum albumin, 100 units/ml penicillin, 100 µg/ml streptomycin, 2 mM glutamine) with the indicated amounts of lipid-free apoA-I, apoA-I-POPC-cholesterol complexes, or spherical HDL. After a 1.5-h incubation at 37 °C, the cells were washed twice at 4 °C with 50 mM Tris-HCl, pH 7.4, 0.15 M NaCl containing 2 mg/ml fatty acid-free bovine serum albumin, followed by one rapid wash with buffer B alone. The cells were then solubilized in lysis buffer (PBS, 1% Triton X-100, 50 µg/ml phenylmethylsulfonyl fluoride, 1 µg/ml pepstatin A, 20 µg/ml aprotinin, and 10 µg/ml leupeptin) and incubated, with shaking, at 4 °C for 30 min. The collected lysates (after scraping) were clarified by centrifugation at 14,000 rpm in a Beckman microcentrifuge for 20 min at 4 °C. The protein concentrations of the cell lysates were determined by the method of Lowry et al. (26). An aliquot of 20-30 µg of the lysate was analyzed by 12% SDS-polyacrylamide gel electrophoresis, and in independent lanes the same ligand used in the binding assay, ranging from 1 to 25 ng, was mixed with the corresponding amount (20-30 µg) of SR-BI cell lysate from control cells not incubated with the ligand. These samples were used to generate the standard curves for quantitation (see below). After electrophoresis, the proteins were transferred to polyvinylidene difluoride membranes at 50 V in 500 mM CAPS-NaOH buffer (pH 11.5) for approximately 1 h. The membranes were blocked overnight at 4 °C, or for 1.5 h at room temperature in PBS containing 0.1% Tween 20 and 5% nonfat dried milk. The membranes were washed three times for 5 min each with PBS 0.1% Tween 20 and 0.5% nonfat dried milk and were incubated for 1 h or overnight in the same solution using monoclonal human anti-apoA-I antibodies diluted 1:2000 (5F-6 antibody, the epitope is amino acids 118-141 of the human apoA-I protein). The membranes were then washed three times for 15 min/wash with PBS, 0.1% Tween 20 and incubated for 1 h in the same solution containing anti-mouse IgG conjugated to horseradish peroxidase diluted 1:5000. Finally, the membranes were washed three times as above in PBS, 0.1% Tween 20. 3',3'-Diaminobenzidine or enhanced chemiluminescence (ECL) reagent was used as substrate of the horseradish peroxidase, and the protein bands on the filters were detected and captured by exposing the blots to Kodak film (Kodak Digital Science Image Station 440CF), according to the manufacturer's instructions. The quantitation of the intensities of the bands was performed using the ImageQuant software. A rectangular box was drawn containing the band of interest, and the net intensity of the band was calculated by subtracting the intensity of an equivalent band-free adjacent area in each lane (background value) from the total intensity of the band-containing box. A standard curve was used to convert the intensity values to ng of ligand protein. The conversion was performed by plotting the standard amount of ligand versus the corresponding intensity. Because the standard curves were reproducibly nonlinear, a polynomial second order regression was used as the best fit for the standard curve. The total binding is expressed as ng of cell-associated HDL, lipid-free apoA-I, or apolipoprotein complex protein per mg of total cell protein.

The cell-associated ligands were analyzed as a function of concentration by nonlinear regression (using the Prism program). The best fit to equations for three models was tested. These are 1) high affinity and saturable binding to a single class of sites on SR-BI; 2) high affinity and saturable binding to two nonequivalent sites; or 3) high affinity and saturable binding to one site plus low affinity and nonsaturable binding to other sites. For the immunoreceptor assays, the best fit was found for the model with high affinity binding to a specific site plus low affinity binding to other sites (background). The equation is as follows,

(Eq. 1)

where "total" represents specific plus nonspecific, B_total is the measured amount of ligand bound, B_max is the amount of ligand bound at saturating concentrations, K_d is the apparent high affinity constant, and NS is the slope of the low affinity nonsaturable process (background). The nonspecific binding values for ldlA[mSR-BI] cells were similar to the total binding values for control ldlA-7 cells.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Development of a New Binding Assay for SR-BI-- We have shown previously that apoA-I is one of the ligands of SR-BI (1). In the current study, we compared the binding of different apoA-I-containing ligands of SR-BI, including HDLs of different densities, discoidal rHDLs containing full-length and truncated apoA-I forms, pre--1 HDL, and lipid-free apoA-I.

The standard binding assay for lipoprotein receptors, such as SR-BI, involves measurement of the association of lipoproteins radioiodinated on their apolipoproteins with cells (radioreceptor assay). Since iodination directly or indirectly (for instance as a consequence of oxidation) might alter the properties of the ligand, we have developed an assay in which unlabeled ligand binding to the receptor is detected by quantitative immunoblotting (immunoreceptor assay). A typical saturation curve for the binding of ¹²⁵I-HDL (d = 1.1-1.13 g/ml) to ldlA[mSR-BI] cells using a radioreceptor assay is shown in Fig. 1A. The total binding values were experimentally determined, whereas the specific and the nonspecific values were obtained by nonlinear regression analysis, as described under "Experimental Procedures." HDL bound to a single class of sites on ldlA[mSR-BI] cells with high affinity, apparent K_d of 16.3 µg of protein/ml and B_max of 450 ng/mg cell protein. B_max varied from experiment to experiment, presumably due to variation in the expression of the SR-BI transgene in the cell line. The apparent K_d value was highly reproducible from experiment to experiment when freshly iodinated HDL was used. However, the K_d did vary depending on the age of the ¹²⁵I-HDL preparation, presumably because of radiolytic/oxidative damage.² For example, the same preparation used in Fig. 1A 3 days after iodination was retested 15 and 55 days postiodination, and the corresponding apparent K_d values were 10.4 ± 2 and 4.9 ± 1 µg of protein/ml, respectively. We typically observed increased binding affinity as the preparations aged. Because of this iodination-dependent variability and the practical limitations of labeling ligands available in low quantities, we developed an alternative assay, the immunoreceptor assay (see "Experimental Procedures"). Fig. 1B shows the binding of unlabeled, spherical HDL (d = 1.13 g/ml) to SR-BI as determined by the immunoreceptor assay. The observed total binding values were determined from the intensity of the bound apoA-I signals in quantitative immunoblots using the standard curve in Fig. 1C. The specific binding and the nonspecific binding values were calculated by nonlinear regression, as described under "Experimental Procedures." The calculated nonspecific binding values for ldlA[mSR-BI] cells were similar to the observed total binding values for untransfected ldlA-7 cells (not shown), which express very little endogenous HDL receptor activity (2). The apparent K_d (16.9 µg of protein/ml) and B_max (370 ng of protein/mg of cell protein) values determined by the immunoreceptor assay were similar to those obtained using the radioreceptor assay and freshly iodinated HDL. Thus, these two assays give similar results, and the new immunoreceptor assay can be used as a simple and powerful alternative to evaluate receptor-binding parameters of a variety of ligands without the need for iodination.

View larger version (32K): [in this window] [in a new window]   Fig. 1.   Spherical HDL binding to SR-BI determined with radioreceptor (A) or immunoreceptor (B and C) assays. A, radioreceptor assay. 125I-HDL binding to ldlA[mSR-BI] cells is shown. On day 0, ldlA[mSR-BI] cells were plated in 24-well dishes in medium A at a density of 4.5-5 × 104 cells/well. On day 2, the cells were incubated for 1.5 h, at 37 °C, with the indicated concentrations of 125I-HDL (d = 1.1-1.13 g/ml, 523 cpm/ng), which was labeled 3 days prior to the experiment. The cell-associated 125I-HDL was determined in duplicates as described under "Experimental Procedures." Open squares represent the observed total cell association values. Specific binding () and nonspecific values () were calculated by nonlinear regression analysis as described under "Experimental Procedures." Incubations of the 125I-HDL in the presence of a 40-fold excess of unlabeled spherical HDL were also performed to independently determine the nonspecific cell association values (not shown). The apparent affinity constant (Kd) value of 16.1 µg of protein/ml was calculated by nonlinear regression as described under "Experimental Procedures." B, immunoreceptor assay. On day 0, ldlA[mSR-BI] and ldlA-7 cells were plated in six-well dishes in medium A (ldlA[mSR-BI]) and in medium B (ldlA-7) at a density of 3 × 105 cells/well. On day 2 after plating, cells were incubated with the indicated concentrations of unlabeled spherical HDL (density 1.13 g/ml) for 1.5 h, at 37 °C. Cell lysates containing receptor-ligand complexes were prepared, separated by 12% SDS-polyacrylamide gel electrophoresis, and blotted into polyvinylidene difluoride filters as described under "Experimental Procedures." The receptor-associated ligand was detected by immunostaining using an enhanced chemiluminescence reagent and was quantitated by photoimaging. The total binding values () were calculated from the observed intensities using a standard curve (C) as described under "Experimental Procedures." The specific () and the nonspecific () binding values and the apparent Kd value of 16.9 µg of protein/ml were calculated by nonlinear regression analysis. C, a standard curve was obtained by fitting a second order polynomial to the immunostaining intensity values from known amounts of the ligand.

High Affinity Binding of Discoidal rHDLs Containing ApoA-I-- In order to characterize further the binding of apoA-I ligands to SR-BI, we tested the role of lipid association on ligand binding affinity. Plasma apoA-I (apoA-Ip) was purified and used for the preparation of rHDL with POPC and unesterified cholesterol, as described under "Experimental Procedures." Most of the discoidal HDL particles in the preparations (80-90%) had diameters of 96-104 Å (not shown). There were less abundant, larger forms with approximate diameters of 120 Å. Fig. 2 shows that ¹²⁵I-rHDL{apoA-Ip} exhibited high affinity, saturable binding to mSR-BI-expressing cells. The apparent K_d value was 1.5 ± 0.2 µg of protein/ml. The data best fit a model for binding of apoA-I to a single class of sites. Similar results were obtained with the immunoreceptor assay (data not shown). The rHDL{apoA-Ip} (predominant population with diameter of 96 Å) is expected to contain approximately two apoA-I molecules per particle (37). The apparent binding affinity of rHDL{apoA-Ip} was at least 1 order of magnitude higher than that of spherical plasma HDL (d = 1.13 g/ml) (16 versus 1.5 µg of protein/ml). Control experiments showed that POPC-cholesterol (2:1) liposomes without apolipoprotein do not bind to SR-BI (data not shown; also see Ref. 1), indicating that the high affinity binding of rHDL to SR-BI was apoA-I-dependent, presumably due to direct association of apoA-I with SR-BI.

View larger version (22K): [in this window] [in a new window]   Fig. 2.   Binding of discoidal 125I-apoA-Ip-POPC-cholesterol complexes (rHDL{apoA-Ip}) to cells expressing mSR-BI. On day 2 after plating, the cells were incubated for 1.5 h at 37 °C with the indicated amounts of 125I-rHDL{apoA-Ip}. The specific binding values shown were obtained by nonlinear regression analysis, as described under "Experimental Procedures." The apparent Kd value was 1.5 µg of protein/ml.

Comparison of the Binding of High and Low Density Spherical HDL,  HDL, Pre--1 HDL, and Lipid-free ApoA-I to SR-BI-- The observation that the affinities of spherical HDL and discoidal rHDL{apoA-Ip} for SR-BI were different prompted us to analyze the binding of different naturally occurring HDL species, including spherical HDL particles of different densities. This analysis involved both direct association and competition assays. Fig. 3A shows the direct association saturation curves for two ¹²⁵I-HDL fractions of different densities. The lower density HDL fraction (filled circles) was 1.11-1.13 g/ml, and the higher density HDL fraction (open circles) was 1.14-1.17 g/ml. These preparations were assayed 15 days after iodination. The binding constants were determined by nonlinear regression, and the apparent K_d values were 11 ± 2 µg of protein/ml for ¹²⁵I-HDL of density 1.11-1.13 g/ml and 37 ± 5 µg of protein/ml for ¹²⁵I-HDL of density 1.14-1.17 g/ml. Fig. 3B shows the inhibition of binding of ¹²⁵I-HDL (d = 1.1-1.12 g/ml) to ldlA[mSR-BI] cells by unlabeled HDL fractions of different densities (1.095-1.149 g/ml). The ability of the HDL fractions to compete for the binding of this low density, high affinity ¹²⁵I-HDL decreased as the density of the HDL particles increased. We have also observed that HDL of  electrophoretic mobility, isolated by immunoaffinity chromatography (27), and the spherical HDL (d = 1.12 g/ml), isolated by zonal ultracentrifugation, did not show significant differences in their abilities to compete for the binding of ¹²⁵I-HDL to SR-BI-expressing cells (data not shown).

View larger version (40K): [in this window] [in a new window]   Fig. 3.   Effects of the density of spherical HDL on SR-BI binding. A, on day 2 after plating, ldlA[mSR-BI] cells were incubated with the indicated concentrations of 125I-labeled HDL fractions of lower (1.11-1.13 g/ml) () or higher (1.14-1.17 g/ml) () densities (isolated by zonal ultracentrifugation). Nonlinear regression analysis of the observed total cell association (see Fig. 1 and "Experimental Procedures") was used to calculate the specific cell association values shown. B, on day 2 after plating, ldlA[mSR-BI] cells were incubated with 10 µg of protein/ml of 125I-HDL (d = 1.1-1.2 g/ml) and either 25 µg (hatched bars) or 75 µg (stippled bars) of protein/ml unlabeled spherical HDL preparations with the indicated densities (g/ml). The values presented are the averages of duplicate determinations. The 100% of control value of cell association, measured in the absence of unlabeled HDL, was 162 ng of 125I-HDL protein/mg of cell protein.

Pre--1 HDL particles are thought to have novel physiological functions that differ from those of spherical HDL (15, 27). In order to compare the interaction with SR-BI of pre--1 HDL, discoidal rHDL{apoA-Ip}, and spherical HDL particles (d = 1.14 g/ml), we examined their abilities to compete for the binding of spherical ¹²⁵I-HDL (d = 1.13 g/ml) to SR-BI. Fig. 4A shows that pre--1 HDL was a poor competitor, compared with the spherical or discoidal rHDL{apoA-Ip} particles. Similar results were observed for the inhibition of the transfer of the lipid dye DiI from DiI-HDL to ldlA[mSR-BI] cells by unlabeled spherical HDL and pre--1 HDL (data not shown). Preliminary direct binding assays, using the immunoreceptor assay did not show SR-BI-dependent binding of pre--1 HDL (data not shown). We also examined the ability of lipid-free apoA-Ip, isolated from plasma, to compete for the binding of spherical ¹²⁵I-HDL (d = 1.14 g/ml) to SR-BI. As previously observed (1), lipid-free apoA-Ip was a poor competitor compared with spherical HDL (d = 1.14 g/ml) or discoidal rHDL{apoA-Ip} particles (Fig. 4B). Numerous direct binding experiments, using either the radioreceptor or the immunoreceptor assay, could not establish an SR-BI-dependent binding of lipid-free apoA-I (data not shown).

View larger version (22K): [in this window] [in a new window]   Fig. 4.   Inhibition of spherical 125I-HDL binding to SR-BI by pre--1 HDL and lipid-free apoA-I. A, on day 2 after plating, ldlA[mSR-BI] cells were incubated with 125I-HDL (10 µg of protein/ml) (density 1.13 g/ml) and the indicated concentrations of spherical HDL (d = 1.14 g/ml), pre--1 HDL, and discoidal rHDL{apoA-Ip}. The values shown are the averages of duplicate determinations. The 100% of control value measured in the absence of competitors was 363 ng of protein/mg of cell protein. Similar results were obtained in three independent experiments. B, on day 2 after plating, ldlA[mSR-BI] cells were incubated with 125I-HDL (5 µg of protein/ml) (d = 1.14 g/ml) and the indicated concentrations of spherical HDL (d = 1.14 g/ml), lipid-free apoA-I, and discoidal rHDL{apoA-Ip}. The values shown are the averages of duplicate determinations. The 100% of control value measured in the absence of competitors was 152 ng of protein/mg of cell protein. Similar results were obtained in six independent experiments.

Effect of ApoA-I Mutations on the Binding of rHDL Particles to SR-BI-- The common feature of all the experiments presented above and in previous studies (1) is that apoA-I is a ligand for SR-BI. This led us to ask if specific domains of the apoA-I molecule were involved in the receptor recognition. To test if the carboxyl-terminal or amino-terminal domains of apoA-I were essential for binding to SR-BI, we designed the following mutant apoA-I forms: a carboxyl-terminal truncated mutant, apoA-I:(185-243); an amino-terminal truncated mutant, apoA-I:(1-59); and a double truncated mutant, lacking both the amino- and the carboxyl-terminal domains, apoA-I:(1-59)(185-243). The apoA-I:(185-243) form was generated by expression of the protein in mammalian C127 cells and contains a 6-residue prosegment, which is not present in plasma apoA-I (38). The amino-terminal truncation, apoA-I_B:(1-59) and the double truncation, apoA-I_B:(1-59)(185-243) were generated by expression of apoA-I using the baculovirus system (the B subscript indicates protein obtained by baculovirus expression) (19, 20). In the baculovirus expression system, the mature apoA-I_B(1-243) synthesized contains a histidine tag at its amino terminus that can be cleaved with the etched virus protease. Discoidal rHDL particles were prepared containing apoA-I recombinant forms and analyzed by native polyacrylamide gel electrophoresis (Table II). The predominant size of rHDL particles containing the wild-type apoA-I, proapoA-I, the amino-terminal deleted, and the double truncated forms was 96-104 Å. The predominant size of rHDL particles containing the carboxyl-terminal truncation was 77-79 Å. These particles are expected to contain two apoA-I molecules per rHDL particle (37). These rHDL particles were tested for binding to SR-BI by both competition for ¹²⁵I-HDL binding and direct association assays.

Fig. 5A shows the inhibition of binding of spherical ¹²⁵I-HDL (d = 1.13 g/ml) by rHDL particles containing proapoA-I:(185-243) or apoA-I_B:(1-59), compared with rHDL{apoA-Ip} and native spherical HDL (d = 1.14 g/ml, dashed line). Both truncated forms, when reconstituted in rHDLs, competed very effectively for the binding of native spherical ¹²⁵I-HDL to SR-BI-expressing cells. rHDL particles containing the full-length proapoA-I recombinant protein competed as well as particles containing the plasma apoA-Ip (data not shown), indicating that the presence of the prosegment did not substantially affect the binding of apoA-I to SR-BI. Similar competition experiments also showed that the presence of the histidine tag in full-length apoA-I in rHDL particles, relative to rHDL particles containing apoA-I in which the tag was removed by proteolysis, did not affect the efficiency of competition for the binding of native spherical ¹²⁵I-HDL to SR-BI (data not shown). Furthermore, the direct binding of rHDL particles containing baculovirus expressed wild-type apoA-I gave similar apparent K_d values in the presence or absence of the His tag on the apoA-I molecule (4 ± 0.5 µg of protein/ml or 135 ± 14 nM equivalent of apoA-I for no His-containing wild-type apoA-I versus 5 ± 1 µg of protein/ml or 168 ± 27 nM equivalent of apoA-I for His-tag containing wild-type apoA-I; data not shown).

View larger version (45K): [in this window] [in a new window]   Fig. 5.   Effects of NH2 terminus truncation, COOH terminus truncation, or both on rHDL binding to SR-BI. On day 2 after plating, association of the indicated lipoproteins with ldlA[mSR-BI] cells was determined using either the radioreceptor (A and C) or the immunoreceptor (B and D) assays as described under "Experimental Procedures." A and C, cells were incubated with 125I-HDL (5 µg of protein/ml) and the indicated concentrations of spherical HDL (dashed line or open circles), rHDL{apoA-Ip} (open diamonds), rHDL{apoA-IB:(1-59)} (filled circles), rHDL{apoA-I:(185-243)} (filled squares), and rHDL{apoA-IB:(1-59)(185-243)} (filled triangles). The values shown are the averages of duplicate determinations. The 100% of control value measured in the absence of competitors was 300 (A and C) ng of protein/mg of cell protein. Similar results were obtained in four independent experiments. B and D, ldlA[mSR-BI] cells (filled circles), or control untransfected ldlA-7 cells (open circles) were incubated with the indicated concentrations of rHDL{proapoA-I:(185-243) or rHDL{apoA-I:(1-59)(His)}, and cell association values (average of duplicate determinations) were determined using the immunoreceptor assay. Values shown in B are representative of two independent experiments using two independent preparations of rHDL{proapoA-I:(185-243)}. Values shown in D are representative of three independent experiments. The apparent Kd values for association with ldlA[mSR-BI] cells (3 ± 0.5 (B) and 7 ± 2 (D) µg of protein/ml) were determined by nonlinear regression analysis.

The efficient competition of rHDL particles containing the amino- or carboxyl-terminal apoA-I truncated forms was confirmed in direct association studies, presented in Fig. 5, B and D. Discoidal rHDLs containing proapoA-I:(185-243) or the apoA-I_B:(1-59) exhibited high affinity saturable binding to a single class of sites on ldlA[mSR-BI] cells, while there was almost no binding to the control untransfected ldlA-7 cells. The respective apparent K_d values were 3 ± 0.5 µg of protein/ml and 7 ± 2 µg of protein/ml. These findings suggest that deletion of either the amino-terminal or the carboxyl-terminal domains of apoA-I alone did not affect substantially the ability of the protein incorporated into particles to bind to SR-BI. In contrast, rHDL particles containing the double truncated mutant apoA-I_B:(1-59)(185-243) competed very poorly for the binding of spherical ¹²⁵I-HDL (Fig. 5C), compared with rHDL{apoA-Ip} particles and spherical HDL. The double truncations of apoA-I may alter the size, shape, and/or composition of the rHDL particles and thus affect the affinity of binding to SR-BI. It seems likely that the conformation of apoA-I may be important for the recognition and binding of different ligands to SR-BI. It appears that optimal binding of discoidal rHDL to SR-BI can be achieved by the central domain of apoA-I (residues 60-184) combined with either the amino or carboxyl-terminal domain. Simultaneous truncation of both these domains might cause conformational changes in rHDL that result in reduced binding affinity. The present study confirms the important role of apoA-I in HDL binding to SR-BI and indicates that the NH₂ and COOH termini of apoA-I independently influence binding to SR-BI, either directly or through changes in the conformation of the core of apoA-I (residues 60-184).

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Affinities of Lipid-associated Forms of ApoA-I for SR-BI-- To assess the binding to SR-BI of apo-A-I-containing ligands without iodinating the apoA-I, we developed an immunoreceptor binding assay. In this assay, the unlabeled receptor-associated ligand is detected by quantitative immunoblotting. This assay is not influenced by potential alterations of the properties of the ligand as a result of radioiodination. It also provides an easier, effective way to assess the binding of ligands that are only available in small quantities and for which iodination presents practical difficulties (e.g. recombinant truncated apoA-I forms). Using either the standard radioreceptor or the new immunoreceptor assay, we have been able to show that spherical HDL (d = 1.1-1.13 g/ml) binds to a single class of sites on SR-BI with an apparent K_d of approximately 16 µg of protein/ml. Discoidal rHDL particles containing plasma apoA-I bind approximately 1 order of magnitude more tightly than spherical HDL (d = 1.1-1.13 g/ml).

The conformation of apoA-I varies when it is lipid-free or incorporated on spherical HDL or discoidal rHDL particles (15, 37). Thus, the differences we observed in the apparent affinities of the spherical HDL or the rHDL particles may be due to differences in the conformation of apoA-I on the surfaces of these particles. These differences may alter the way the ligand is presented to the receptor. The discoidal rHDLs used were formed by the association of apoA-I with phospholipids and cholesterol at a molar ratio of 1 apoA-I:100 POPC:10 cholesterol. It has been previously reported that the rHDL discs prepared with specific phospholipids, such as POPC or DPPC, and apoA-I have discrete and reproducible sizes, apoA-I compositions, and apoA-I conformations. For example, the POPC-A-I particles have been described that consist of discs with diameters of 96, 86, and 77 Å and contain two apoA-I molecules per particle (37). It has been suggested that in the 96-, 86-, and 77-Å particles, eight, seven and six apoA-I helices, respectively, make contact with lipids. rHDL particles with three and four apoA-I molecules have also been reported (37, 39-41). Therefore, it is possible that the different number of apoA-I molecules per particle and/or the different conformation of apoA-I within a specific particle could affect the affinity of apoA-I binding to SR-BI. Two models have been proposed for the arrangement of apoA-I helices on these particles. The classic picket fence model suggests that the helices are arranged parallel to the fatty acid chains of the phospholipid (42, 43). The belt model for discoidal HDL suggests that A/B dimer containing two antiparallel apoA-I chains wraps around the disc (44-46). In the belt model, the carboxyl-terminal apoA-I helix appears to be important for dimer formation (44, 46). Our results suggest that carboxyl terminus-dependent structural features do not appear to play an important role in discoidal rHDL binding. In both models, polyvalent binding of multiple apoA-I molecules could facilitate ligand-receptor interactions by cross-linking adjacent SR-BI molecules or binding to multiple independent sites on a single receptor, thus increasing the apparent binding affinity.

Particle Density, Lipid, and Apoprotein Composition Affect Ligand Binding Affinity-- It has been suggested that newly synthesized lipid-free apoA-I, or apoA-I that dissociates from HDL or other lipoproteins, recruits phospholipids from cell membranes to form discoidal pre--1 HDL (15). These particles can accept cholesterol from cell membranes and are converted into larger discoidal pre--2 HDL (47, 48). Lecithin:cholesterol acyltransferase-mediated cholesterol esterification converts the discoidal pre--2 particles into spherical -migrating HDL particles (49, 50). HDL₃ may then receive lipids from other lipoproteins or from cells to be converted into HDL₂. Plasma HDL may also consist of particles containing apoA-I (LpA-I) or apoA-I and apoA-II (Lp(AI:AII)) (51-55). The majority of Lp(AI) floats at the density of HDL₂, whereas the majority of Lp(AI:AII) floats at the density of HDL₃. It has been shown that HDL₂ and HDL₃ contain four and three apoA-I molecules per particle, respectively (56).

The current study suggests that in addition to the shape of the HDL particles (discoidal versus spherical) the lipid and apolipoprotein composition of the HDL particles may affect their affinity for SR-BI. The first experiment showed a reduction in the affinity of the HDL isolated by zonal ultracentrifugation as its density increased. The gradual reduction in affinity may result from differences in the sizes or the compositions of the particles (e.g. number of apoA-I molecules/particle) or both, which may alter the manner in which apoA-I is presented to the receptor. The second experiment showed strikingly diminished ability of both pre--1 HDL isolated from plasma and lipid-free apoA-I, relative to spherical HDL, to compete with native ¹²⁵I-HDL binding to SR-BI. We previously reported that lipid-free apoA-I could compete partially with ¹²⁵I-HDL for binding to SR-BI (~36% inhibition of the binding of 10 µg of protein/ml ¹²⁵I-HDL by 50 µg of protein/ml lipid-free apoA-I (1)). While we confirmed this finding of partial inhibition in the current study, the more extensive analysis reported here, using both radioreceptor and immunoreceptor assays, clearly shows that lipid-free apoA-I is a much less effective competitor than native HDL or rHDL particles. The findings for lipid-free apoA-I and pre--1 HDL, which comprises apoA-I combined with only a small amount of phospholipid (15), both indicate an important role for the interaction of apoA-I with lipids in controlling the interaction of apoA-I with SR-BI. Previous studies established that the lipid composition of pre--1 HDL species as well as the conformation of apoA-I in the pre--1 particles differ from those of spherical HDL (15, 27). These differences presumably contribute to the differences in interactions with SR-BI. Based on these data and many previous studies (4, 7, 9, 10, 57-59), we suggest the following. SR-BI binds most tightly to large, relatively low density, cholesteryl ester-rich HDL particles to maximize the efficiency of cholesterol transport via selective uptake. As a consequence of such selective uptake, the particles become smaller. Indeed, in the absence of SR-BI in vivo (9), HDL particles are abnormally large. Larger HDL particles have been shown to have longer in vivo plasma residence, as determined by the fractional catabolic rates, than smaller HDL particles (60). It seems likely that SR-BI mediates both the transfer of cholesteryl ester from lipid-rich HDL to target cells (liver, steroidogenic tissue) and participates with proteins such as lipases and cholesteryl ester transfer protein (59, 61-67) in the remodeling of HDL to generate smaller particles. The smaller particles, which bind less tightly to SR-BI, either serve as substrates for regenerating larger cholesteryl ester-rich HDLs, presumably by the action of ABC1 (68-71) and lecithin:cholesterol acyltransferase, or are catabolized after filtration by the kidney, presumably via cubilin-mediated endocytosis (72, 73).

Effect of ApoA-I Mutations on the Binding of rHDL Particles to SR-BI-- Recent studies have explored the roles of the amino and carboxyl termini of apoA-I on the protein's structure and function. For example, deletion of the amino-terminal residues 1-43 reduces the stability of apoA-I in the lipid-free state (44, 74). In addition, the carboxyl terminus (residues 185-243) has been shown to be important for binding to phospholipids and lipoproteins (18, 75) and may have other functions (76). Furthermore, the central core region, 68-185, which contains six amphipathic -helices, is important for other apoA-I functions. In particular, helices 6 and 7 are important for the activation of lecithin:cholesterol acyltransferase (18, 77-79). It has been shown that deletions of the amino (residues 1-43) or the carboxyl-terminal residues (residues 185-243) of apoA-I did not alter significantly the helical content of lipid-free apoA-I (80).

In the current studies, we examined the association with SR-BI of rHDL particles containing mutant apoA-I forms with either single deletions of the 59 amino-terminal residues or the 58 carboxyl-terminal residues or the double deletion mutant in which both sets of termini were removed. The affinities of rHDL particles containing the single terminal deletion mutant forms were similar to those of rHDL particles comprising the full-length apoA-I. The small changes in the apparent K_d values of the rHDLs with the single truncations may reflect differences in the particle sizes of the different apoA-I forms. Simultaneous deletion of both terminal domains was associated with substantially reduced capacity of the corresponding rHDL particles to compete for the binding of spherical ¹²⁵I-HDL. These data raise the possibility that both the amino or the carboxyl-terminal domains can bind independently to SR-BI. In support of this interpretation, a recent independent report, which appeared during the preparation of this manuscript, showed that discoidal rHDL particles containing peptides representing the amino-terminal (residues 1-85) or the carboxyl-terminal region (residues 149-243) of apoA-I bind with high affinity to SR-BI (81). An alternative interpretation could be that both terminal domains influence a feature(s) of the structure of the core of apoA-I that is critical for binding to SR-BI. Thus, it is possible that the central helices (residues 60-184) in the proper conformation contribute independently to receptor binding. The diminished affinity of the double mutant may then have resulted from an altered conformation of the central helices because of these mutations. The current data do not allow us to identify precisely where on apoA-I the binding site(s) for SR-BI is located.

Additional in vitro and in vivo studies will be required to determine if alterations in the conformation, sequence, or structure of apoA-I significantly influence selective uptake of cholesterol mediated by SR-BI.

	ACKNOWLEDGEMENTS

We thank especially Xiaoping Li as well as Marsha Penman, Michael Gigliotti, and Cheryl England for assistance in preparing lipoproteins; Robert Rosenberg and Patti Christie for providing access to and advice in using the Kodak Digital Science Image Station; and Xiangju Gu and Bernando Trigatti for helpful discussions.

	FOOTNOTES

^* This work was supported by National Institutes of Health Grants BMH4-CT983699, HL48739, HL41484, HL52212, and HL31210; a grant from the Joseph Drown Foundation; and a gift from Donald Yellon.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ These authors contributed equally to this work.

^§§ To whom correspondence should be addressed. Tel.: 617-638-5085; Fax: 617-638-5141; E-mail: vzannis@bu.edu.

Published, JBC Papers in Press, May 2, 2000, DOI 10.1074/jbc.M002310200

² K. N. Liadaki, T. Liu, S. Xu, B. Y. Ishida, P. N. Duchateaux, J. P. Krieger, J. Kane, M. Krieger, and V. I. Zannis, unpublished observations.

	ABBREVIATIONS

The abbreviations used are: SR-BI, scavenger receptor class B type I; mSR-BI, murine SR-BI; HDL, high density lipoprotein; apoA-I, apolipoprotein A-I; ldlA, low density lipoprotein receptor-deficient Chinese hamster ovary cell line; ldlA[mSR-BI] cells, mSR-BI-expressing ldlA cells; POPC, 1-palmitoyl-2-oleoyl-L-phosphatidylcholine; apoA-Ip, plasma apolipoprotein A-I; rHDL, discoidal reconstituted HDL particle(s); CAPS, 3-(cyclohexylamino)propanesulfonic acid.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				M. A. Liz, C. M. Gomes, M. J. Saraiva, and M. M. Sousa ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity J. Lipid Res., November 1, 2007; 48(11): 2385 - 2395. [Abstract] [Full Text] [PDF]

				C. Cavelier, L. Rohrer, and A. von Eckardstein ATP-Binding Cassette Transporter A1 Modulates Apolipoprotein A-I Transcytosis Through Aortic Endothelial Cells Circ. Res., November 10, 2006; 99(10): 1060 - 1066. [Abstract] [Full Text] [PDF]

				P. V. Subbaiah, L. R. Gesquiere, and K. Wang Regulation of the selective uptake of cholesteryl esters from high density lipoproteins by sphingomyelin J. Lipid Res., December 1, 2005; 46(12): 2699 - 2705. [Abstract] [Full Text] [PDF]

				M. C. de Beer, D. van der Westhuyzen, N. L. Whitaker, N. R. Webb, and F. C. de Beer SR-BI-mediated selective lipid uptake segregates apoA-I and apoA-II catabolism J. Lipid Res., October 1, 2005; 46(10): 2143 - 2150. [Abstract] [Full Text] [PDF]

				C. Voisset, N. Callens, E. Blanchard, A. Op De Beeck, J. Dubuisson, and N. Vu-Dac High Density Lipoproteins Facilitate Hepatitis C Virus Entry through the Scavenger Receptor Class B Type I J. Biol. Chem., March 4, 2005; 280(9): 7793 - 7799. [Abstract] [Full Text] [PDF]

				L. Cai, M. C. de Beer, F. C. de Beer, and D. R. van der Westhuyzen Serum Amyloid A Is a Ligand for Scavenger Receptor Class B Type I and Inhibits High Density Lipoprotein Binding and Selective Lipid Uptake J. Biol. Chem., January 28, 2005; 280(4): 2954 - 2961. [Abstract] [Full Text] [PDF]

				T. J. F. Nieland, A. Chroni, M. L. Fitzgerald, Z. Maliga, V. I. Zannis, T. Kirchhausen, and M. Krieger Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide J. Lipid Res., July 1, 2004; 45(7): 1256 - 1265. [Abstract] [Full Text] [PDF]

				M. C. de Beer, L. W. Castellani, L. Cai, A. J. Stromberg, F. C. de Beer, and D. R. van der Westhuyzen ApoA-II modulates the association of HDL with class B scavenger receptors SR-BI and CD36 J. Lipid Res., April 1, 2004; 45(4): 706 - 715. [Abstract] [Full Text] [PDF]

				V. M. Paromov and R. E. Morton Lipid Transfer Inhibitor Protein Defines the Participation of High Density Lipoprotein Subfractions in Lipid Transfer Reactions Mediated by Cholesterol Ester Transfer Protein (CETP) J. Biol. Chem., October 17, 2003; 278(42): 40859 - 40866. [Abstract] [Full Text] [PDF]

				B. L. Trigatti, M. Krieger, and A. Rigotti Influence of the HDL Receptor SR-BI on Lipoprotein Metabolism and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1732 - 1738. [Abstract] [Full Text] [PDF]

				N. Wang and A. R. Tall Regulation and Mechanisms of ATP-Binding Cassette Transporter A1-Mediated Cellular Cholesterol Efflux Arterioscler. Thromb. Vasc. Biol., July 1, 2003; 23(7): 1178 - 1184. [Abstract] [Full Text] [PDF]

				A. Rigotti, H. E. Miettinen, and M. Krieger The Role of the High-Density Lipoprotein Receptor SR-BI in the Lipid Metabolism of Endocrine and Other Tissues Endocr. Rev., June 1, 2003; 24(3): 357 - 387. [Abstract] [Full Text] [PDF]

				S. T. Thuahnai, S. Lund-Katz, G. M. Anantharamaiah, D. L. Williams, and M. C. Phillips A quantitative analysis of apolipoprotein binding to SR-BI: multiple binding sites for lipid-free and lipid-associated apolipoproteins J. Lipid Res., June 1, 2003; 44(6): 1132 - 1142. [Abstract] [Full Text] [PDF]

				M. Lee, P. T. Kovanen, G. Tedeschi, E. Oungre, G. Franceschini, and L. Calabresi Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux J. Lipid Res., March 1, 2003; 44(3): 539 - 546. [Abstract] [Full Text] [PDF]

				P. Mardones, A. Pilon, M. Bouly, D. Duran, T. Nishimoto, H. Arai, K. F. Kozarsky, M. Altayo, J. F. Miquel, G. Luc, et al. Fibrates Down-regulate Hepatic Scavenger Receptor Class B Type I Protein Expression in Mice J. Biol. Chem., February 28, 2003; 278(10): 7884 - 7890. [Abstract] [Full Text] [PDF]

				A. Chroni, T. Liu, I. Gorshkova, H.-Y. Kan, Y. Uehara, A. von Eckardstein, and V. I. Zannis The Central Helices of ApoA-I Can Promote ATP-binding Cassette Transporter A1 (ABCA1)-mediated Lipid Efflux. AMINO ACID RESIDUES 220-231 OF THE WILD-TYPE ApoA-I ARE REQUIRED FOR LIPID EFFLUX IN VITRO AND HIGH DENSITY LIPOPROTEIN FORMATION IN VIVO J. Biol. Chem., February 21, 2003; 278(9): 6719 - 6730. [Abstract] [Full Text] [PDF]

				R. E. Temel, J. S. Parks, and D. L. Williams Enhancement of Scavenger Receptor Class B Type I-mediated Selective Cholesteryl Ester Uptake from apoA-I-/- High Density Lipoprotein (HDL) by Apolipoprotein A-I Requires HDL Reorganization by Lecithin Cholesterol Acyltransferase J. Biol. Chem., February 7, 2003; 278(7): 4792 - 4799. [Abstract] [Full Text] [PDF]

				T. J. F. Nieland, M. Penman, L. Dori, M. Krieger, and T. Kirchhausen Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI PNAS, November 26, 2002; 99(24): 15422 - 15427. [Abstract] [Full Text] [PDF]

				B. Liu and M. Krieger Highly Purified Scavenger Receptor Class B, Type I Reconstituted into Phosphatidylcholine/Cholesterol Liposomes Mediates High Affinity High Density Lipoprotein Binding and Selective Lipid Uptake J. Biol. Chem., September 6, 2002; 277(37): 34125 - 34135. [Abstract] [Full Text] [PDF]

				G. Marsche, A. Hammer, O. Oskolkova, K. F. Kozarsky, W. Sattler, and E. Malle Hypochlorite-modified High Density Lipoprotein, a High Affinity Ligand to Scavenger Receptor Class B, Type I, Impairs High Density Lipoprotein-dependent Selective Lipid Uptake and Reverse Cholesterol Transport J. Biol. Chem., August 23, 2002; 277(35): 32172 - 32179. [Abstract] [Full Text] [PDF]

				R. E. Temel, R. L. Walzem, C. L. Banka, and D. L. Williams Apolipoprotein A-I Is Necessary for the in Vivo Formation of High Density Lipoprotein Competent for Scavenger Receptor BI-mediated Cholesteryl Ester-selective Uptake J. Biol. Chem., July 12, 2002; 277(29): 26565 - 26572. [Abstract] [Full Text] [PDF]

				X. Li, H.-Y. Kan, S. Lavrentiadou, M. Krieger, and V. Zannis Reconstituted Discoidal ApoE-Phospholipid Particles Are Ligands for the Scavenger Receptor BI. THE AMINO-TERMINAL 1-165 DOMAIN OF ApoE SUFFICES FOR RECEPTOR BINDING J. Biol. Chem., June 7, 2002; 277(24): 21149 - 21157. [Abstract] [Full Text] [PDF]

				T. Liu, M. Krieger, H.-Y. Kan, and V. I. Zannis The Effects of Mutations in Helices 4 and 6 of ApoA-I on Scavenger Receptor Class B Type I (SR-BI)-mediated Cholesterol Efflux Suggest That Formation of a Productive Complex between Reconstituted High Density Lipoprotein and SR-BI Is Required for Efficient Lipid Transport J. Biol. Chem., June 7, 2002; 277(24): 21576 - 21584. [Abstract] [Full Text] [PDF]

				S. T. Thuahnai, S. Lund-Katz, D. L. Williams, and M. C. Phillips Scavenger Receptor Class B, Type I-mediated Uptake of Various Lipids into Cells. INFLUENCE OF THE NATURE OF THE DONOR PARTICLE INTERACTION WITH THE RECEPTOR J. Biol. Chem., November 16, 2001; 276(47): 43801 - 43808. [Abstract] [Full Text] [PDF]

				M. C. de Beer, D. M. Durbin, L. Cai, A. Jonas, F. C. de Beer, and D. R. van der Westhuyzen Apolipoprotein A-I conformation markedly influences HDL interaction with scavenger receptor BI J. Lipid Res., February 1, 2001; 42(2): 309 - 313. [Abstract] [Full Text]

				F. C. de Beer, P. M. Connell, J. Yu, M. C. de Beer, N. R. Webb, and D. R. van der Westhuyzen HDL modification by secretory phospholipase A2 promotes scavenger receptor class B type I interaction and accelerates HDL catabolism J. Lipid Res., November 1, 2000; 41(11): 1849 - 1857. [Abstract] [Full Text]

				X. Gu, K. Kozarsky, and M. Krieger Scavenger Receptor Class B, Type I-mediated [3H]Cholesterol Efflux to High and Low Density Lipoproteins Is Dependent on Lipoprotein Binding to the Receptor J. Biol. Chem., September 22, 2000; 275(39): 29993 - 30001. [Abstract] [Full Text] [PDF]

				W. Chen, D. L. Silver, J. D. Smith, and A. R. Tall Scavenger Receptor-BI Inhibits ATP-binding Cassette Transporter 1- mediated Cholesterol Efflux in Macrophages J. Biol. Chem., September 29, 2000; 275(40): 30794 - 30800. [Abstract] [Full Text] [PDF]

				N. Wang, D. L. Silver, P. Costet, and A. R. Tall Specific Binding of ApoA-I, Enhanced Cholesterol Efflux, and Altered Plasma Membrane Morphology in Cells Expressing ABC1 J. Biol. Chem., October 13, 2000; 275(42): 33053 - 33058. [Abstract] [Full Text] [PDF]

				M. C. de Beer, D. M. Durbin, L. Cai, N. Mirocha, A. Jonas, N. R. Webb, F. C. de Beer, and D. R. van der Westhuyzen Apolipoprotein A-II Modulates the Binding and Selective Lipid Uptake of Reconstituted High Density Lipoprotein by Scavenger Receptor BI J. Biol. Chem., May 4, 2001; 276(19): 15832 - 15839. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 275/28/21262    most recent M002310200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liadaki, K. N. Articles by Zannis, V. I. Search for Related Content PubMed PubMed Citation Articles by Liadaki, K. N. Articles by Zannis, V. I. Social Bookmarking                      What's this?